Contact
searchSearch
HMP Global
Login

Advertisement

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

Cholangiocarcinoma Specialty Channel

Cholangiocarcinoma
Specialty Channel
Conference Coverage
Addition of Stereotactic Body Radiotherapy to Chemotherapy for Patients With Inoperable, Locally Advanced Cholangiocarcinoma
05/28/2024
According to a phase 2 trial presented at the 2024 ASCO Annual Meeting, adding stereotactic body radiotherapy to chemotherapy did not prolong progression-free survival for patients with advanced cholangiocarcinoma, however more mature data is...
According to a phase 2 trial presented at the 2024 ASCO Annual Meeting, adding stereotactic body radiotherapy to chemotherapy did not prolong progression-free survival for patients with advanced cholangiocarcinoma, however more mature data is...
According to a phase 2 trial...
05/28/2024
Oncology
News
Laparoscopic Hemihepatectomy vs Open Hemihepatectomy Among Patients With Primary or Metastatic Liver Tumors
05/17/2024
Stephanie Holland
Results from the ORANGE II PLUS trial demonstrated that a minimally invasive, laparoscopic approach to hemihepatectomy shortened time to functional recovery compared to open, major hemihepatectomy among patients with primary or metastatic...
Results from the ORANGE II PLUS trial demonstrated that a minimally invasive, laparoscopic approach to hemihepatectomy shortened time to functional recovery compared to open, major hemihepatectomy among patients with primary or metastatic...
Results from the ORANGE II PLUS...
05/17/2024
Oncology
Conference Coverage
Tinegotinib Monotherapy Shows Efficacy Among Patients With Advanced/Metastatic Cholangiocarcinoma
01/20/2024
Results from a phase 2 study found tinegotinib monotherapy demonstrated promising clinical efficacy and tolerable safety among patients with advanced/metastatic cholangiocarcinoma previously treated with an FGFR inhibitor and patients with...
Results from a phase 2 study found tinegotinib monotherapy demonstrated promising clinical efficacy and tolerable safety among patients with advanced/metastatic cholangiocarcinoma previously treated with an FGFR inhibitor and patients with...
Results from a phase 2 study...
01/20/2024
Oncology
Conference Coverage
Hepatic Arterial Infusion Pump Chemotherapy Improves Survival Outcomes for Intrahepatic Cholangiocarcinoma
01/19/2024
According to results from a phase 2 trial, combining hepatic arterial infusion pump chemotherapy with systemic therapy was associated with improved 3-year overall survival among patients with advanced intrahepatic cholangiocarcinoma.
According to results from a phase 2 trial, combining hepatic arterial infusion pump chemotherapy with systemic therapy was associated with improved 3-year overall survival among patients with advanced intrahepatic cholangiocarcinoma.
According to results from a...
01/19/2024
Oncology
Conference Coverage
Atezolizumab and Bevacizumab Plus Chemotherapy Provides Modest PFS Benefit in Advanced Biliary Tract Cancer
01/19/2024
First-line treatment with atezolizumab and bevacizumab plus chemotherapy provides PFS advantage vs atezolizumab plus placebo and chemotherapy for patients with advanced biliary tract cancer, according to findings from the phase 2 IMbrave151...
First-line treatment with atezolizumab and bevacizumab plus chemotherapy provides PFS advantage vs atezolizumab plus placebo and chemotherapy for patients with advanced biliary tract cancer, according to findings from the phase 2 IMbrave151...
First-line treatment with...
01/19/2024
Oncology
News
Pembrolizumab Plus Chemotherapy Approved for Treatment of Patients With Biliary Tract Cancer
11/02/2023
On November 1, 2023, the FDA granted approval to pembrolizumab, with gemcitabine and cisplatin, for the treatment of locally advanced unresectable or metastatic biliary tract cancer.
On November 1, 2023, the FDA granted approval to pembrolizumab, with gemcitabine and cisplatin, for the treatment of locally advanced unresectable or metastatic biliary tract cancer.
On November 1, 2023, the FDA...
11/02/2023
Oncology
News
Zanidatamab Shows Promise for HER2-Positive, Unresectable Biliary Tract Cancer
07/20/2023
In a phase 2b study, zanidatamab demonstrated meaningful clinical benefit with a manageable safety profile among patients with HER2-positive, unresectable, locally advanced or metastatic biliary tract cancer.
In a phase 2b study, zanidatamab demonstrated meaningful clinical benefit with a manageable safety profile among patients with HER2-positive, unresectable, locally advanced or metastatic biliary tract cancer.
In a phase 2b study, zanidatamab...
07/20/2023
Oncology
Conference Coverage
NUC-1031 Did Not Prolong Overall Survival for Patients With Advanced Biliary Tract Cancers
06/29/2023
According to phase 3 data presented at the 2023 ESMO World Congress on Gastrointestinal Cancers, NUC-1031 plus cisplatin did not improve the overall survival among patients with advanced biliary tract cancers, vs gemcitabine-cisplatin.
According to phase 3 data presented at the 2023 ESMO World Congress on Gastrointestinal Cancers, NUC-1031 plus cisplatin did not improve the overall survival among patients with advanced biliary tract cancers, vs gemcitabine-cisplatin.
According to phase 3 data...
06/29/2023
Oncology
Quiz
Adjuvant or Neoadjuvant Chemotherapy for Non-Metastatic Cholangiocarcinoma
06/15/2023
True or False: Patients with non-metastatic cholangiocarcinoma who received adjuvant or neoadjuvant chemotherapy had better median overall survival compared to patients who had surgery only.
True or False: Patients with non-metastatic cholangiocarcinoma who received adjuvant or neoadjuvant chemotherapy had better median overall survival compared to patients who had surgery only.
True or False: Patients with...
06/15/2023
Oncology
Quiz
Cholangioscopy for Diagnosis of Cholangiocarcinoma
06/15/2023
When used to diagnose cholangiocarcinoma, or bile duct cancer, cholangioscopy yields a sensitivity of about ___.
When used to diagnose cholangiocarcinoma, or bile duct cancer, cholangioscopy yields a sensitivity of about ___.
When used to diagnose...
06/15/2023
Oncology
Conference Coverage
Novel FGFR TKI Demonstrated Efficacy and Safety for Patients With Advanced Intrahepatic Cholangiocarcinoma
06/02/2023
The FGFR-selective tyrosine kinase inhibitor (TKI) HMPL-453 was found to be effective and safe for patients with advanced intrahepatic cholangiocarcinoma.
The FGFR-selective tyrosine kinase inhibitor (TKI) HMPL-453 was found to be effective and safe for patients with advanced intrahepatic cholangiocarcinoma.
The FGFR-selective tyrosine...
06/02/2023
Oncology

Advertisement

News

Conference Coverage
Addition of Stereotactic Body Radiotherapy to Chemotherapy for Patients With Inoperable, Locally Advanced Cholangiocarcinoma
05/28/2024
According to a phase 2 trial presented at the 2024 ASCO Annual Meeting, adding stereotactic body radiotherapy to chemotherapy did not prolong progression-free survival for patients with advanced cholangiocarcinoma, however more mature data is...
According to a phase 2 trial presented at the 2024 ASCO Annual Meeting, adding stereotactic body radiotherapy to chemotherapy did not prolong progression-free survival for patients with advanced cholangiocarcinoma, however more mature data is...
According to a phase 2 trial...
05/28/2024
Oncology
News
Laparoscopic Hemihepatectomy vs Open Hemihepatectomy Among Patients With Primary or Metastatic Liver Tumors
05/17/2024
Stephanie Holland
Results from the ORANGE II PLUS trial demonstrated that a minimally invasive, laparoscopic approach to hemihepatectomy shortened time to functional recovery compared to open, major hemihepatectomy among patients with primary or metastatic...
Results from the ORANGE II PLUS trial demonstrated that a minimally invasive, laparoscopic approach to hemihepatectomy shortened time to functional recovery compared to open, major hemihepatectomy among patients with primary or metastatic...
Results from the ORANGE II PLUS...
05/17/2024
Oncology
Conference Coverage
Tinegotinib Monotherapy Shows Efficacy Among Patients With Advanced/Metastatic Cholangiocarcinoma
01/20/2024
Results from a phase 2 study found tinegotinib monotherapy demonstrated promising clinical efficacy and tolerable safety among patients with advanced/metastatic cholangiocarcinoma previously treated with an FGFR inhibitor and patients with...
Results from a phase 2 study found tinegotinib monotherapy demonstrated promising clinical efficacy and tolerable safety among patients with advanced/metastatic cholangiocarcinoma previously treated with an FGFR inhibitor and patients with...
Results from a phase 2 study...
01/20/2024
Oncology
Conference Coverage
Hepatic Arterial Infusion Pump Chemotherapy Improves Survival Outcomes for Intrahepatic Cholangiocarcinoma
01/19/2024
According to results from a phase 2 trial, combining hepatic arterial infusion pump chemotherapy with systemic therapy was associated with improved 3-year overall survival among patients with advanced intrahepatic cholangiocarcinoma.
According to results from a phase 2 trial, combining hepatic arterial infusion pump chemotherapy with systemic therapy was associated with improved 3-year overall survival among patients with advanced intrahepatic cholangiocarcinoma.
According to results from a...
01/19/2024
Oncology
Conference Coverage
Atezolizumab and Bevacizumab Plus Chemotherapy Provides Modest PFS Benefit in Advanced Biliary Tract Cancer
01/19/2024
First-line treatment with atezolizumab and bevacizumab plus chemotherapy provides PFS advantage vs atezolizumab plus placebo and chemotherapy for patients with advanced biliary tract cancer, according to findings from the phase 2 IMbrave151...
First-line treatment with atezolizumab and bevacizumab plus chemotherapy provides PFS advantage vs atezolizumab plus placebo and chemotherapy for patients with advanced biliary tract cancer, according to findings from the phase 2 IMbrave151...
First-line treatment with...
01/19/2024
Oncology
News
Pembrolizumab Plus Chemotherapy Approved for Treatment of Patients With Biliary Tract Cancer
11/02/2023
On November 1, 2023, the FDA granted approval to pembrolizumab, with gemcitabine and cisplatin, for the treatment of locally advanced unresectable or metastatic biliary tract cancer.
On November 1, 2023, the FDA granted approval to pembrolizumab, with gemcitabine and cisplatin, for the treatment of locally advanced unresectable or metastatic biliary tract cancer.
On November 1, 2023, the FDA...
11/02/2023
Oncology
News
Zanidatamab Shows Promise for HER2-Positive, Unresectable Biliary Tract Cancer
07/20/2023
In a phase 2b study, zanidatamab demonstrated meaningful clinical benefit with a manageable safety profile among patients with HER2-positive, unresectable, locally advanced or metastatic biliary tract cancer.
In a phase 2b study, zanidatamab demonstrated meaningful clinical benefit with a manageable safety profile among patients with HER2-positive, unresectable, locally advanced or metastatic biliary tract cancer.
In a phase 2b study, zanidatamab...
07/20/2023
Oncology
Conference Coverage
NUC-1031 Did Not Prolong Overall Survival for Patients With Advanced Biliary Tract Cancers
06/29/2023
According to phase 3 data presented at the 2023 ESMO World Congress on Gastrointestinal Cancers, NUC-1031 plus cisplatin did not improve the overall survival among patients with advanced biliary tract cancers, vs gemcitabine-cisplatin.
According to phase 3 data presented at the 2023 ESMO World Congress on Gastrointestinal Cancers, NUC-1031 plus cisplatin did not improve the overall survival among patients with advanced biliary tract cancers, vs gemcitabine-cisplatin.
According to phase 3 data...
06/29/2023
Oncology
Conference Coverage
Novel FGFR TKI Demonstrated Efficacy and Safety for Patients With Advanced Intrahepatic Cholangiocarcinoma
06/02/2023
The FGFR-selective tyrosine kinase inhibitor (TKI) HMPL-453 was found to be effective and safe for patients with advanced intrahepatic cholangiocarcinoma.
The FGFR-selective tyrosine kinase inhibitor (TKI) HMPL-453 was found to be effective and safe for patients with advanced intrahepatic cholangiocarcinoma.
The FGFR-selective tyrosine...
06/02/2023
Oncology
Conference Coverage
Nanvuranlat Demonstrated Clinical Activity for Advanced, Refractory Biliary Tract Cancers
01/20/2023
According to a phase 2 trial presented at the 2023 ASCO Gastrointestinal Cancers Symposium, the LAT1-inhibitor nanvuranlat significantly improved progression-free survival for patients with advanced refractory biliary tract cancers, compared...
According to a phase 2 trial presented at the 2023 ASCO Gastrointestinal Cancers Symposium, the LAT1-inhibitor nanvuranlat significantly improved progression-free survival for patients with advanced refractory biliary tract cancers, compared...
According to a phase 2 trial...
01/20/2023
Oncology

Quiz
Adjuvant or Neoadjuvant Chemotherapy for Non-Metastatic Cholangiocarcinoma
06/15/2023
True or False: Patients with non-metastatic cholangiocarcinoma who received adjuvant or neoadjuvant chemotherapy had better median overall survival compared to patients who had surgery only.
True or False: Patients with non-metastatic cholangiocarcinoma who received adjuvant or neoadjuvant chemotherapy had better median overall survival compared to patients who had surgery only.
True or False: Patients with...
06/15/2023
Oncology
Quiz
Cholangioscopy for Diagnosis of Cholangiocarcinoma
06/15/2023
When used to diagnose cholangiocarcinoma, or bile duct cancer, cholangioscopy yields a sensitivity of about ___.
When used to diagnose cholangiocarcinoma, or bile duct cancer, cholangioscopy yields a sensitivity of about ___.
When used to diagnose...
06/15/2023
Oncology
Quiz
Incidence of IDH Mutations in Cholangiocarcinoma
05/09/2023
In what percentage of patients with cholangiocarcinoma does an IDH mutation occur?
In what percentage of patients with cholangiocarcinoma does an IDH mutation occur?
In what percentage of patients...
05/09/2023
Oncology
Quiz
Quiz: IDH Mutations in Biliary Tract Cancers
04/11/2023
Which type of biliary tract cancer is more likely to be IDH-mutant?
Which type of biliary tract cancer is more likely to be IDH-mutant?
Which type of biliary tract...
04/11/2023
Oncology
Quiz
Quiz: Outcomes of Liver Transplant vs Resection for Perihilar Cholangiocarcinoma
12/01/2022
How did the outcomes of patients with unresectable perihilar cholangiocarcinoma who were treated with neoadjuvant chemoradiotherapy and liver transplant compare to the outcomes of patients with perihilar cholangiocarcinoma who underwent...
How did the outcomes of patients with unresectable perihilar cholangiocarcinoma who were treated with neoadjuvant chemoradiotherapy and liver transplant compare to the outcomes of patients with perihilar cholangiocarcinoma who underwent...
How did the outcomes of patients...
12/01/2022
Oncology
Quiz
Quiz: Trastuzumab Biosimilar Plus FOLFOX for HER2-Positive Biliary Tract Cancer
11/30/2022
What was the approximate objective response rate seen for patients with HER2-positive biliary tract cancer treated with the trastuzumab-pkrb biosimilar plus modified FOLFOX chemotherapy in the second- or third-line setting?
What was the approximate objective response rate seen for patients with HER2-positive biliary tract cancer treated with the trastuzumab-pkrb biosimilar plus modified FOLFOX chemotherapy in the second- or third-line setting?
What was the approximate...
11/30/2022
Oncology
Quiz
Quiz: In the phase 2 FIDES-01 study, derazantinib showed clinical benefit in patients with intrahepatic cholangiocarcinoma and which types of FGFR2 genetic mutations, aberrations, or fusions?
11/02/2022
In the phase 2 FIDES-01 study, derazantinib showed clinical benefit in patients with interhepatic cholangiocarcinoma and which types of FGFR2 genetic mutations, aberrations, or fusions?
In the phase 2 FIDES-01 study, derazantinib showed clinical benefit in patients with interhepatic cholangiocarcinoma and which types of FGFR2 genetic mutations, aberrations, or fusions?
In the phase 2 FIDES-01 study,...
11/02/2022
Oncology
Test Your Knowledge
Quiz: What Test Can Be Used to Compare OS, DFS in ICC?
02/24/2022
Which test can be used to compare overall survival (OS) and disease-free survival (DFS) in intrahepatic cholangiocarcinoma (ICC)?
Which test can be used to compare overall survival (OS) and disease-free survival (DFS) in intrahepatic cholangiocarcinoma (ICC)?
Which test can be used to...
02/24/2022
Oncology
Quiz
Quiz: Which Clinical Trial Was the Basis for Pemagatinib Approval?
02/14/2022
The FDA’s approval of pemigatinib was based on a clinical trial of 107 pretreated patients with locally advanced or metastatic cholangiocarcinoma and _____ fusion or rearrangement.
The FDA’s approval of pemigatinib was based on a clinical trial of 107 pretreated patients with locally advanced or metastatic cholangiocarcinoma and _____ fusion or rearrangement.
The FDA’s approval of...
02/14/2022
Oncology
Test Your Knowledge
Quiz: Does Infigratinib Yield a Survival Benefit in Patients with Cholangiocarcinoma and FGFR2 Fusions?
08/28/2020
True or false: Infigratinib did not yield a survival benefit in patients with cholangiocarcinoma and FGFR2 fusions.
True or false: Infigratinib did not yield a survival benefit in patients with cholangiocarcinoma and FGFR2 fusions.
True or false: Infigratinib did...
08/28/2020
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Recent News

News
Laparoscopic Hemihepatectomy vs Open Hemihepatectomy Among Patients With Primary or Metastatic Liver Tumors
05/17/2024
Stephanie Holland
Results from the ORANGE II PLUS trial demonstrated that a minimally invasive, laparoscopic approach to hemihepatectomy shortened time to functional recovery compared to open, major hemihepatectomy among patients with primary or metastatic...
Results from the ORANGE II PLUS trial demonstrated that a minimally invasive, laparoscopic approach to hemihepatectomy shortened time to functional recovery compared to open, major hemihepatectomy among patients with primary or metastatic...
Results from the ORANGE II PLUS...
05/17/2024
Oncology
News
Pembrolizumab Plus Chemotherapy Approved for Treatment of Patients With Biliary Tract Cancer
11/02/2023
On November 1, 2023, the FDA granted approval to pembrolizumab, with gemcitabine and cisplatin, for the treatment of locally advanced unresectable or metastatic biliary tract cancer.
On November 1, 2023, the FDA granted approval to pembrolizumab, with gemcitabine and cisplatin, for the treatment of locally advanced unresectable or metastatic biliary tract cancer.
On November 1, 2023, the FDA...
11/02/2023
Oncology
News
Zanidatamab Shows Promise for HER2-Positive, Unresectable Biliary Tract Cancer
07/20/2023
In a phase 2b study, zanidatamab demonstrated meaningful clinical benefit with a manageable safety profile among patients with HER2-positive, unresectable, locally advanced or metastatic biliary tract cancer.
In a phase 2b study, zanidatamab demonstrated meaningful clinical benefit with a manageable safety profile among patients with HER2-positive, unresectable, locally advanced or metastatic biliary tract cancer.
In a phase 2b study, zanidatamab...
07/20/2023
Oncology
News
Annual MRI for Patients With Primary Sclerosing Cholangitis Failed to Provide Long-Term Cholangiocarcinoma Survival Benefit
11/21/2022
Among patients with primary sclerosing cholangitis, yearly surveillance by MRI was not able to detect cholangiocarcinoma early enough to convey a long-term survival benefit.
Among patients with primary sclerosing cholangitis, yearly surveillance by MRI was not able to detect cholangiocarcinoma early enough to convey a long-term survival benefit.
Among patients with primary...
11/21/2022
Oncology
News
Trastuzumab Biosimilar Plus FOLFOX Shows Promise for HER2-Positive Biliary Tract Cancers
11/10/2022
In a phase 2 trial, trastuzumab biosimilar plus FOLFOX demonstrated promising activity and acceptable safety among patients with HER2-positive biliary tract cancers that had progressed on gemcitabine and cisplatin chemotherapy regimens.
In a phase 2 trial, trastuzumab biosimilar plus FOLFOX demonstrated promising activity and acceptable safety among patients with HER2-positive biliary tract cancers that had progressed on gemcitabine and cisplatin chemotherapy regimens.
In a phase 2 trial, trastuzumab...
11/10/2022
Oncology
News
Novel FGFR2 Inhibitor Shows Promise in Patients With Cholangiocarcinoma and an FGFR2-Fusion or Rearrangement
10/20/2022
According to a phase 1/2 study, the novel FGFR2-inhibitor RLY-4008 showed promised in patients with cholangiocarcinoma and an FGFR2 fusion or rearrangement.
According to a phase 1/2 study, the novel FGFR2-inhibitor RLY-4008 showed promised in patients with cholangiocarcinoma and an FGFR2 fusion or rearrangement.
According to a phase 1/2 study,...
10/20/2022
Oncology
News
FDA Approves Futibatinib for Intrahepatic Cholangiocarcinoma With FGFR2 Gene Fusions or Rearrangements
10/03/2022
On September 30, 2022, the US FDA granted accelerated approval to futibatinib, 20 mg orally daily, for patients with locally advanced or metastatic intrahepatic cholangiocarcinoma with FGFR2 gene fusions or rearrangements.
On September 30, 2022, the US FDA granted accelerated approval to futibatinib, 20 mg orally daily, for patients with locally advanced or metastatic intrahepatic cholangiocarcinoma with FGFR2 gene fusions or rearrangements.
On September 30, 2022, the US...
10/03/2022
Oncology
News
Derazantinib Showed Clinical Benefit as a Second-Line Treatment for Patients With Intrahepatic Cholangiocarcinoma and EGFR2 Aberrations
09/30/2022
Results from a phase 2 trial showed that derazantinib as a second-line treatment resulted in meaningful clinical benefit for patients with intrahepatic cholangiocarcinoma and EGFR2 aberrations.
Results from a phase 2 trial showed that derazantinib as a second-line treatment resulted in meaningful clinical benefit for patients with intrahepatic cholangiocarcinoma and EGFR2 aberrations.
Results from a phase 2 trial...
09/30/2022
Oncology
News
Nivolumab Plus Gemcitabine and S-1 Demonstrates Potential in Advanced Biliary Tract Cancer
09/28/2022
Results from a phase 2 trial show that modified gemcitabine and S-1 plus nivolumab is a safe and promising regimen for patients with advanced biliary tract cancer, with impaired function of chromatin remodeling genes as a potential surrogate...
Results from a phase 2 trial show that modified gemcitabine and S-1 plus nivolumab is a safe and promising regimen for patients with advanced biliary tract cancer, with impaired function of chromatin remodeling genes as a potential surrogate...
Results from a phase 2 trial...
09/28/2022
Oncology
News
Nivolumab Added to Chemotherapy or Ipilimumab Offers No Survival Benefit in Advanced Biliary Tract Cancer
08/31/2022
Findings from a phase 2 trial suggest adding nivolumab to either chemotherapy or ipilimumab provides no PFS benefit in the first-line treatment of patients with advanced biliary tract cancer.
Findings from a phase 2 trial suggest adding nivolumab to either chemotherapy or ipilimumab provides no PFS benefit in the first-line treatment of patients with advanced biliary tract cancer.
Findings from a phase 2 trial...
08/31/2022
Oncology
News
Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation
08/08/2024
Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.
Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.
Results from a phase 2 study...
08/08/2024
Oncology
FDA Approval
FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma
08/08/2024
The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.
The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.
The US Food and Drug...
08/08/2024
Oncology
News
Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer
08/07/2024
According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.
According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.
According to results from the...
08/07/2024
Oncology
News
Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL
08/07/2024
A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.
A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.
A recent study demonstrated that...
08/07/2024
Oncology
News
Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer
08/07/2024
Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.
Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.
Results from a phase 2 study...
08/07/2024
Oncology
FDA Approval
FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma
08/06/2024
Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.
Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.
Based on results from the INDIGO...
08/06/2024
Oncology
FDA Approval
FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma
08/02/2024
On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...
On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...
On August 2, 2024, the US Food...
08/02/2024
Oncology
FDA Approval
FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer
08/01/2024
The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.
The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.
The FDA approved dostarlimab...
08/01/2024
Oncology
News
Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML
08/01/2024
The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.
The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.
The first-line combination of...
08/01/2024
Oncology
News
Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas
08/01/2024
In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...
In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...
In the phase 1 trial, the...
08/01/2024
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use

Advertisement

Advertisement